KEYNOTE-010研究中帕博利珠单抗对比多西他赛治疗既往治疗后晚期PD-L1表达NSCLC的健康相关生活质量
KEYNOTE-010 II/III期研究显示,在既往治疗过的PD-L1表达(肿瘤比例评分≥1%)晚期NSCLC患者中,帕博利珠单抗较多西他赛显著延长总生存。本文报告健康相关生活质量结果:帕博利珠单抗组从基线至12周QLQ-C30整体健康状况/生活质量评分优于多西他赛组(无论剂量或TPS状态,均未达显著),QLQ-LC13复合终点至恶化时间在帕博利珠单抗10 mg/kg组较多西他赛组显著延长(名义双侧p=0.03),2 mg/kg组未达显著。
要点
- 帕博利珠单抗组从基线至12周QLQ-C30整体健康状况/生活质量评分优于多西他赛组,但未达统计学显著。
- 帕博利珠单抗组整体健康状况/生活质量恶化患者较少、改善患者较多。
- 帕博利珠单抗10 mg/kg组QLQ-LC13复合终点真实至恶化时间较多西他赛组显著延长(名义双侧p=0.03),2 mg/kg组未达显著。
核心结论
- 这些发现提示,在该NSCLC患者人群中,帕博利珠单抗较多西他赛更大程度地维持或改善健康相关生活质量和症状。
研究设计与样本
- KEYNOTE-010为II/III期研究(ClinicalTrials.gov,NCT01905657),患者按1:1:1随机接受帕博利珠单抗2 mg/kg或10 mg/kg每3周一次,或多西他赛75 mg/m2每3周一次。
- 健康相关生活质量采用欧洲癌症研究与治疗组织(EORTC)生活质量问卷核心30(QLQ-C30)、EORTC QLQ-肺癌13(QLQ-LC13)和EuroQoL-5D评估。
- 关键分析包括整体健康状况/生活质量评分、功能和症状领域从基线至第12周的平均变化,以及QLQ-LC13咳嗽、呼吸困难、胸痛复合终点的至恶化时间。
主要发现
- 三种量表患者报告结局依从性均高。
- 帕博利珠单抗组从基线至12周QLQ-C30整体健康状况/生活质量评分优于多西他赛组,无论帕博利珠单抗剂量或肿瘤比例评分状态(未达显著)。
- 与多西他赛组相比,帕博利珠单抗组整体健康状况/生活质量恶化患者较少、改善患者较多。
- 帕博利珠单抗组许多EORTC症状领域报告名义显著改善,多西他赛组报告名义显著恶化。
- QLQ-LC13复合终点真实至恶化时间在帕博利珠单抗10 mg/kg组较多西他赛组显著延长(名义双侧p=0.03),2 mg/kg组未达显著。
关键数值与推荐
- 帕博利珠单抗2 mg/kg或10 mg/kg每3周一次,多西他赛75 mg/m2每3周一次。
- 患者为既往治疗过的PD-L1表达(肿瘤比例评分≥1%)晚期NSCLC。
- QLQ-LC13复合终点真实至恶化时间:帕博利珠单抗10 mg/kg组对比多西他赛组名义双侧p=0.03,2 mg/kg组未达显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1-expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here. METHODS: Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ-Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain. RESULTS: Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had "deteriorated" status and more had "improved" status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose. CONCLUSIONS: These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.
引用
- Barlesi F, Garon EB, Kim DW, et al. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019. PMID: 30711649. doi:10.1016/j.jtho.2019.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。